Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

被引：3
|
作者：
Aguiar, Pedro, Jr. [1 ]
Perry, Luke A. [2 ]
Lopes, Gilberto L., Jr. [3 ]
机构：
[1] Univ Fed Sao Paulo, Oncol & Hematol Dept, Clin Oncol Sect, Sao Paulo, Brazil
[2] Monash Univ Sch Med, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
LUNG CANCER MANAGEMENT | 2016年 / 5卷 / 03期
关键词：
cost-effectiveness; health technology assessment; immunotherapy; lung cancer;
D O I：
10.2217/lmt-2016-0016
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：119 / 122
页数：4
相关论文
共 50 条
  • [31] Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer.
    Li, Wenqian
    Li, Lingyu
    Chen, Naifei
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
    Gray, Steven G.
    Cuffe, Sinead
    Finn, Stephen P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : E142 - E144
  • [33] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
    Minari, Roberta
    Bonatti, Francesco
    Mazzaschi, Giulia
    Dodi, Alessandra
    Facchinetti, Francesco
    Gelsomino, Francesco
    Cinquegrani, Gloria
    Squadrilli, Anna
    Bordi, Paola
    Buti, Sebastiano
    Bersanelli, Melissa
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Quaini, Federico
    Ardizzoni, Andrea
    Tiseo, Marcello
    TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
  • [34] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [35] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [36] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [37] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
    Zhao, S.
    Li, X.
    Wang, S.
    Wang, Y.
    Huang, D.
    Da, Y.
    Song, Z.
    Chen, J.
    Manegold, C.
    Peng, L.
    Xu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651
  • [38] Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
    Ospina Serrano, A. V.
    Aguiar, P., Jr.
    Bruges, R.
    Gonzalez Diaz, J.
    Del Giglio, A.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S824 - S824
  • [39] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    Drug Safety, 2019, 42 : 281 - 294
  • [40] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    DRUG SAFETY, 2019, 42 (02) : 281 - 294
12345